J&J: promising data on dengue fever
(CercleFinance.com) - The Janssen pharmaceutical companies of Johnson & Johnson (Janssen) today announced promising data from a Phase 2a study evaluating JNJ-1802, a first-in-class oral antiviral in development for the prevention of dengue fever.
The data showed that the compound induced antiviral activity against dengue fever (DENV-3) in humans, compared with placebo, and was "safe and well tolerated", the laboratory said.
The data was announced at the annual meeting of the American Society of Tropical Medicine & Hygiene in Chicago, Illinois.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The data showed that the compound induced antiviral activity against dengue fever (DENV-3) in humans, compared with placebo, and was "safe and well tolerated", the laboratory said.
The data was announced at the annual meeting of the American Society of Tropical Medicine & Hygiene in Chicago, Illinois.
Copyright (c) 2023 CercleFinance.com. All rights reserved.